www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

US EUROPE AFRICA ASIA 中文
Business / Industries

Pharmaceutical sector ripe for innovation

By Helen Chui (China Daily) Updated: 2014-07-15 06:57

Pharmaceutical sector ripe for innovation

The booth of Novartis Group (China) at an international medical conference in Beijing. The European Union Industrial Research and Development Investment Scoreboard 2013 shows that the pharmaceutical and biotech industry is the biggest spender on R&D in Europe. WU CHANGQING/CHINA DAILY

Innovation is a bold pursuit for any organization or government. In striving for something new and something better, there is one self-evident truth: Innovation is all about making the world better for all of us.

As China's economy is being steered toward a growth model in which knowledge and technology are playing a key role, innovation is becoming increasingly important and vigorously promoted. Premier Li Keqiang reaffirmed this position recently, saying China will strive to make innovation a driving force of the country's economic upgrading.

China has made great efforts to increase its innovation capabilities to drive further economic growth by generating new products, markets and jobs, leading to increased productivity and upgraded industries.

Pharmaceutical sector ripe for innovation
Pharmaceutical sector ripe for innovation
Implementing measurable and practical innovation and creativity is not a simple task. This is especially evident in the pharmaceutical industry; it is estimated to take $1 billion to $2 billion and 15 to 20 years to bring a new product to market.

The European Union Industrial Research and Development Investment Scoreboard 2013 shows the pharmaceutical and biotech industry is the biggest spender on R&D in Europe and, globally, five pharma and biotech companies, including Novartis International AG, are among the top 10 R&D investors.

Meaningful innovation takes time and a long-term outlook. New medications and treatments can take many years to pass through the development pipeline.

There are positive signs that China's pharmaceutical industry is making innovative R&D efforts. To support their efforts and elevate the industry's innovation capabilities, we need to build a thriving R&D ecosystem for which a rewarding policy environment is a key element.

China's government has shown a commitment to R&D investment. However, translating the investment into innovation in the form of products or business culture requires additional efforts, including an open and fair regulatory environment.

The rate of technology commercialization in China is 10 percent, while that for Organization of Economic Cooperation and Development countries is 40 percent. China could rethink its innovation framework to ensure its robust investment will lead to improved innovation capabilities and greater transfer of technology to the marketplace.

Three main pillars are crucial for the creation of a robust national framework to support innovation in the healthcare field.

First, upgrade public investment in basic R&D. The ratio of government investment in basic R&D is improving and increased financial support to universities and public research institutes would have a major effect.

Previous Page 1 2 Next Page

Hot Topics

Editor's Picks
...
...
主站蜘蛛池模板: 欧美一区二区在线观看视频 | 国产一在线精品一区在线观看 | 久久这里只有精品视频99 | 日韩有码第一页 | 亚洲国产一区二区a毛片 | 高清波多野结衣一区二区三区 | xxxwww欧美性 | 国内一级特黄女人精品片 | 精品久久免费观看 | 国产真实乱系列2孕妇 | 俄罗斯一级毛片免费播放 | 成人国产精品视频频 | 日本一区不卡视频 | 欧美成人免费看片一区 | 自拍视频啪 | 免费一级片视频 | 久久精品国产99久久72 | 欧美成人性色大片在线观看 | 99久久精品男女性高爱 | 久久精品亚瑟全部免费观看 | 91久久亚洲最新一本 | 国产成人久久一区二区三区 | 91精品国产免费久久久久久青草 | 一级国产a级a毛片无卡 | 性欧美另类老妇高清 | 加勒比色综合久久久久久久久 | 中文字幕一区二区小泽玛利亚 | 亚洲精品高清久久 | 国产一级片大全 | 看一级特黄a大片日本片 | www中文字幕在线观看 | 欧美成人综合在线观看视频 | 99视频在线观看视频一区 | 韩国一级毛片在线观看 | 久久国产精品免费看 | 99久久免费视频在线观看 | 欧美日一级片 | 国产三级日本三级美三级 | 一级毛片不卡片免费观看 | 欧美精品日本一级特黄 | 久久久久久久性潮 |